2023
Tau epicenter identification and connectivity in clinically heterogeneous Alzheimer’s disease variants
Trainer A, Xu W, Chase A, O'Dell R, Tun S, Li J, Ju S, van Dyck C, Mecca A, Fredricks C. Tau epicenter identification and connectivity in clinically heterogeneous Alzheimer’s disease variants. Alzheimer's & Dementia 2023, 19 DOI: 10.1002/alz.079435.Peer-Reviewed Original ResearchAmnestic Alzheimer's diseaseLogopenic variant primary progressive aphasiaPosterior cortical atrophyFunctional connectivity mapsHigher tau burdenFunctional connectivityTau burdenAlzheimer's diseaseConnectivity mapsLongitudinal tau-PETSpread of tauVariant primary progressive aphasiaFusiform gyrusFrontal eye fieldPrimary progressive aphasiaBrains of participantsTau PET scansSuperior parietal lobulePatient-specific biomarkersCortical atrophyCommon subtypeTau-PETHealthy controlsParietooccipital cortexPET scansCharacteristics and Outcomes of Younger Adult Patients (Pts) with Myelodysplastic Syndromes (MDS): A Multicenter Retrospective Study
Abaza Y, Xie Z, Burkart M, Badar T, Desai P, Shallis R, Patel A, Cohen-Nowak A, Oh T, Walker C, Easwar N, Kewan T, Cannova J, Bell-Burdett K, Al Ali N, Sallman D, Roboz G, Carraway H, Zeidan A, Patnaik M, Altman J, Komrokji R. Characteristics and Outcomes of Younger Adult Patients (Pts) with Myelodysplastic Syndromes (MDS): A Multicenter Retrospective Study. Blood 2023, 142: 3232. DOI: 10.1182/blood-2023-188328.Peer-Reviewed Original ResearchHigh-risk myelodysplastic syndromeMedian overall survivalMulticenter retrospective studyRisk myelodysplastic syndromesOverall survivalYA groupMyelodysplastic syndromeYounger ptsComplete remissionAllo-SCTBaseline characteristicsFrontline therapyHematologic improvementMedian ageRetrospective studyCommon subtypeBlasts-2Exact testUpfront allogeneic stem cell transplantationIntermediate-risk myelodysplastic syndromesTherapy-related myelodysplastic syndromeAllogeneic stem cell transplantationDe novo myelodysplastic syndromeExcess blasts-2Marrow complete remissionClinicopathologic characterization of hepatocellular adenomas in men: a multicenter experience
González I, Torbenson M, Sharifai N, Byrnes K, Chatterjee D, Kakar S, Yeh M, Wu T, Zhang X, Jain D. Clinicopathologic characterization of hepatocellular adenomas in men: a multicenter experience. Human Pathology 2023, 138: 24-33. PMID: 37245629, DOI: 10.1016/j.humpath.2023.05.010.Peer-Reviewed Original ResearchConceptsHepatocellular adenomaHepatocellular carcinomaMalignant transformationMulticenter experienceMean ageWorld Health Organization classificationConcomitant hepatocellular carcinomaAndrogen receptor expressionBenign liver neoplasmUnclassified hepatocellular adenomaUncertain malignant potentialInflammatory hepatocellular adenomaΒ-catenin-activated hepatocellular adenomaClinicopathologic characterizationEntire cohortHCA casesCommon subtypeMalignant potentialOrganization classificationReproductive ageAllred score systemResection casesReceptor expressionHepatocellular neoplasmsLiver neoplasms
2022
T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Brammer J, Clemens MW, Dogan A, Foss F, Ghione P, Goodman AM, Guitart J, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Jones A, Kallam A, Kim YH, Kumar K, Mehta-Shah N, Olsen EA, Rajguru SA, Rozati S, Said J, Shaver A, Shea L, Shinohara MM, Sokol L, Torres-Cabala C, Wilcox R, Wu P, Zain J, Dwyer M, Sundar H. T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2022, 20: 285-308. PMID: 35276674, DOI: 10.6004/jnccn.2022.0015.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaT-cell lymphomaAnaplastic large cell lymphomaLarge cell lymphomaAnaplastic lymphoma kinaseCell lymphomaLymphoma kinaseTreatment of PTCLNCCN Clinical Practice GuidelinesAngioimmunoblastic T-cell lymphomaClinical practice guidelinesNon-Hodgkin lymphomaMature T cellsNCCN guidelinesLymphoproliferative disordersCommon subtypePractice guidelinesT cellsLymphomaHeterogeneous groupGuidelinesSubtypesDiagnosisOncology
2021
Bundling cancer subtypes in value-based care: A pilot analysis of lymphoma episodes in the Oncology Care Model.
Yue A, Chaudhry B, Schleicher S, Huntington S, Lyss A, Connor N, Tran L, Adelson K. Bundling cancer subtypes in value-based care: A pilot analysis of lymphoma episodes in the Oncology Care Model. Journal Of Clinical Oncology 2021, 39: e18850-e18850. DOI: 10.1200/jco.2021.39.15_suppl.e18850.Peer-Reviewed Original ResearchCommunity oncology practicesAcademic medical centerOncology Care ModelEpisode costsWaldenstrom's macroglobulinemiaCare modelCancer subtypesLarge community oncology practiceProportion of subtypesLarge academic medical centerICD-10 diagnosisIntensity of careValue-based careCohort studyClinical featuresCommon subtypeFrequent subtypeOncology practiceLymphoma populationLymphoma subtypesMedical CenterHeterogeneous diseaseInappropriate shiftIndividual subtypesSubtypesHow we treat advanced stage cutaneous T‐cell lymphoma – mycosis fungoides and Sézary syndrome
Sethi TK, Montanari F, Foss F, Reddy N. How we treat advanced stage cutaneous T‐cell lymphoma – mycosis fungoides and Sézary syndrome. British Journal Of Haematology 2021, 195: 352-364. PMID: 33987825, DOI: 10.1111/bjh.17458.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAdrenal Cortex HormonesAgedAntibodies, MonoclonalAntineoplastic AgentsBexaroteneBiomarkers, TumorClinical Trials as TopicCombined Modality TherapyDelayed DiagnosisDiagnosis, DifferentialElectronsHematopoietic Stem Cell TransplantationHistone Deacetylase InhibitorsHumansInterferon-alphaMaleMycosis FungoidesNeoplasm StagingNeoplastic Stem CellsPhotopheresisPrognosisPUVA TherapyRetinoidsSezary SyndromeSignal TransductionSkin NeoplasmsT-Lymphocyte SubsetsConceptsT-cell lymphomaSézary syndromeMultidisciplinary careCutaneous T-cell lymphoma mycosis fungoidesMycosis fungoides/Sézary syndromeCutaneous T-cell lymphomaLines of therapyAdditional treatment optionsNon-Hodgkin lymphomaDuration of useCumulative drug toxicityEarly referralRecurrent diseaseDiagnostic delayPatients' qualityTreatment optionsCommon subtypeTreatable diseaseRare subsetDrug toxicityLymphomaSyndromeDiseasePresent reviewCareCan primary hepatocellular carcinoma histomorphology predict extrahepatic metastasis?
Kumar D, Hafez O, Jain D, Zhang X. Can primary hepatocellular carcinoma histomorphology predict extrahepatic metastasis? Human Pathology 2021, 113: 39-46. PMID: 33905775, DOI: 10.1016/j.humpath.2021.04.008.Peer-Reviewed Original ResearchConceptsMetastatic hepatocellular carcinomaHepatocellular carcinomaHistologic patternHistomorphologic featuresPrimary tumorMetastatic tumorsMacrotrabecular-massive hepatocellular carcinomaCommon histologic patternPathogenesis of metastasisSignificant intratumoral heterogeneityExtrahepatic metastasesLymph nodesMicrovascular invasionAdrenal glandCommon subtypeNoncirrhotic liverCirrhotic liverCommon siteMetastatic tissuesLarge cohortAbdominal cavityHCC subtypesPathology archivesMetastasisHCC metastasis
2019
Hematologic Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Systematic Review of Case-Reports and Case-Series
Gnanapandithan K, Kharel P, Grimshaw A, Giri S. Hematologic Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Systematic Review of Case-Reports and Case-Series. Blood 2019, 134: 3606. DOI: 10.1182/blood-2019-132203.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsAutoimmune hemolytic anemiaPure red cell aplasiaImmune thrombocytopeniaThrombotic thrombocytopenic purpuraCase reportICI therapyIntravenous immunoglobulinHematopoietic growth factorsCheckpoint inhibitorsMost patientsAdverse eventsHemophagocytic lymphohistiocytosisSupportive treatmentCase seriesClinical presentationCommon subtypeTreatment strategiesEligibility criteriaSystematic reviewNon-small cell lung cancerOrgan systemsGrowth factorAnti-thymocyte globulinHigh-dose corticosteroidsNCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019.
Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Bartlett NL, Caimi PF, Chang JE, Chavez JC, Christian B, Fayad LE, Glenn MJ, Habermann TM, Lee Harris N, Hernandez-Ilizaliturri F, Kaminski MS, Kelsey CR, Khan N, Krivacic S, LaCasce AS, Mehta A, Nademanee A, Rabinovitch R, Reddy N, Reid E, Roberts KB, Smith SD, Snyder ED, Swinnen LJ, Vose JM, Dwyer MA, Sundar H. NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019. Journal Of The National Comprehensive Cancer Network 2019, 17: 650-661. PMID: 31200358, DOI: 10.6004/jnccn.2019.0029.Peer-Reviewed Original ResearchMeSH KeywordsAdultAftercareAntineoplastic Agents, ImmunologicalDrug Resistance, NeoplasmHumansImmunotherapy, AdoptiveLymphoma, FollicularLymphoma, Large B-Cell, DiffuseMedical OncologyNeoplasm Recurrence, LocalNeoplasm StagingPhosphoinositide-3 Kinase InhibitorsReceptors, Chimeric AntigenSignal TransductionUnited StatesConceptsDiffuse large B-cell lymphomaB-cell lymphomaRefractory follicular lymphomaFollicular lymphomaRefractory diffuse large B-cell lymphomaCAR T-cell therapyLarge B-cell lymphomaPoor clinical outcomeT-cell therapyNovel treatment optionsNCCN guidelinesClinical outcomesHodgkin's lymphomaTreatment optionsCommon subtypeHistologic transformationB cellsLymphomaTreatmentImportant updatesPatientsTherapySubtypesTFLDNA Damage Response Pathway Alteration in Locally Advanced Clear-Cell Renal-Cell Carcinoma Is Associated With a Poor Outcome
Na J, Nagaya N, Rha K, Han W, Kim I. DNA Damage Response Pathway Alteration in Locally Advanced Clear-Cell Renal-Cell Carcinoma Is Associated With a Poor Outcome. Clinical Genitourinary Cancer 2019, 17: 299-305.e1. PMID: 31204211, DOI: 10.1016/j.clgc.2019.05.004.Peer-Reviewed Original ResearchConceptsClear cell renal cell carcinomaDisease-free survivalAdvanced clear cell renal cell carcinomaDDR pathway alterationPathway alterationsLocalized Clear Cell Renal Cell CarcinomaDecreased disease-free survivalTCGA databaseShorter disease-free survivalCopy number alterationsTherapeutic agentsCox regression analysisT3-4 diseaseClear-Cell RenalRenal cell carcinomaDDR pathwaysPresence of mutationsT3a diseaseNeoadjuvant therapyOverall survivalPoor outcomeCell carcinomaCommon subtypeDisease progressionKidney cancerClassification of Subtypes of Apert Syndrome, Based on the Type of Vault Suture Synostosis
Lu X, Sawh-Martinez R, Forte A, Wu R, Cabrejo R, Wilson A, Steinbacher DM, Alperovich M, Alonso N, Persing JA. Classification of Subtypes of Apert Syndrome, Based on the Type of Vault Suture Synostosis. Plastic & Reconstructive Surgery Global Open 2019, 7: e2158. PMID: 31044122, PMCID: PMC6467634, DOI: 10.1097/gox.0000000000002158.Peer-Reviewed Original ResearchApert syndromeCranial base angulationClass IClass IICommon subtypeCoronal synostosisObstructive sleep apneaCranial baseApert syndrome patientsBilateral coronal synostosisClassification of subtypesUnilateral lambdoid synostosisUnilateral coronal synostosisAirway compromiseSleep apneaAnatomic deformityTreatment choiceSyndrome patientsPosterior aspectOropharyngeal spaceCT scanCranial base angleCleft palateClass IIISyndrome
2018
Ischemic Colitis
Johnson D, Davis K. Ischemic Colitis. 2018, 311-323. DOI: 10.1007/978-3-319-96286-3_26.Peer-Reviewed Original ResearchMultisystem organ failureIschemic colitisAcute lower GIReversible clinical symptomsSevere ischemic colitisCardiac eventsPostoperative periodCardiac surgeryOrgan failureAnnual incidenceIschemic injuryClinical symptomsCommon subtypeTransmural necrosisGastrointestinal tractLower GIPatientsColitisPopulation agesCommon formMost casesSurgeryEtiologyInjurySymptomsAccessory liver within the thoracic cavity
Adin M, Çetinçakmak M, Deniz M, Göya C. Accessory liver within the thoracic cavity. Surgical And Radiologic Anatomy 2018, 40: 1085-1091. PMID: 29860552, DOI: 10.1007/s00276-018-2046-9.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsSurgical interventionAccessory liverThoracic cavityLiver tissueOptimal diagnostic modalityNon-operative managementUnnecessary surgical interventionImaging modalitiesAccessible imaging modalityColor Doppler imagingDiagnostic imaging modalitiesUnnecessary radiation exposureType IEctopic liverPresent studyCase reportCommon subtypeThoracic surgeryClinical managementNatural courseDifferential diagnosisDiagnostic modalitiesPostmortem examinationDoppler imagingBiopsy procedure
2015
Osteonecrosis of the Jaw in Association With Chemotherapy in the Setting of Cutaneous T-Cell Lymphoma
DeSesa CR, Appugounder S, Haberland C, Johnson MP. Osteonecrosis of the Jaw in Association With Chemotherapy in the Setting of Cutaneous T-Cell Lymphoma. Journal Of Oral And Maxillofacial Surgery 2015, 74: 292-301. PMID: 26296596, DOI: 10.1016/j.joms.2015.07.019.Peer-Reviewed Original ResearchConceptsT-cell lymphomaCutaneous T-cell lymphomaSézary syndromeMycosis fungoidesIntraoral manifestationsCases of osteonecrosisNon-Hodgkin lymphomaLate-stage variantsDiffuse erythrodermaMultifocal osteonecrosisOral manifestationsOverall prognosisCutaneous ulcersErythematous lesionsCase reportCommon subtypePrevalent subtypeAggressive formCutaneous edemaSyndromeFungoidesOsteonecrosisPatientsLymphomaCommon formA Novel Small-Molecule Inhibitor Targeting CREB-CBP Complex Possesses Anti-Cancer Effects along with Cell Cycle Regulation, Autophagy Suppression and Endoplasmic Reticulum Stress
Lee JW, Park HS, Park SA, Ryu SH, Meng W, Jürgensmeier JM, Kurie JM, Hong WK, Boyer JL, Herbst RS, Koo JS. A Novel Small-Molecule Inhibitor Targeting CREB-CBP Complex Possesses Anti-Cancer Effects along with Cell Cycle Regulation, Autophagy Suppression and Endoplasmic Reticulum Stress. PLOS ONE 2015, 10: e0122628. PMID: 25897662, PMCID: PMC4405579, DOI: 10.1371/journal.pone.0122628.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdenocarcinoma of LungAnilidesAntineoplastic AgentsApoptosis Regulatory ProteinsAutophagyAutophagy-Related Protein 7Bcl-2-Like Protein 11Cell Cycle CheckpointsCell Line, TumorCyclic AMP Response Element-Binding ProteinDrug Screening Assays, AntitumorEndoplasmic Reticulum StressHumansInhibitory Concentration 50Kaplan-Meier EstimateLung NeoplasmsMembrane ProteinsMolecular Docking SimulationOrganophosphatesPeptide FragmentsProportional Hazards ModelsProtein BindingProto-Oncogene ProteinsSialoglycoproteinsUbiquitin-Activating EnzymesConceptsLung cancerHuman lung cancer cell linesEndoplasmic reticulum (ER) stress markersLung cancer cell linesNovel therapeutic strategiesPotential therapeutic targetAnti-cancer effectsNovel small molecule inhibitorPotential therapeutic agentCyclic AMP response element binding proteinAccumulation of p62Response element-binding proteinEndoplasmic reticulum stressCancer cell linesCancer deathCommon subtypeCell cycle arrestLung adenocarcinomaNew therapiesTherapeutic strategiesSmall molecule inhibitorsTherapeutic targetElement-binding proteinStress markersTherapeutic agents
2013
Lymphoma
Kelsey C, Wilson L. Lymphoma. Medical Radiology 2013, 257-278. DOI: 10.1007/174_2013_830.Peer-Reviewed Original ResearchClinical practiceSignificant prognostic significancePrognostic scoring systemNon-Hodgkin lymphomaDistinct treatment approachesPositron emission tomographyAssess prognosisPrognostic significanceCommon subtypePathological factorsRadiological imagingHeterogeneous presentationLymphoid systemTreatment approachesScoring systemEmission tomographyDistinct diseasesLymphomaGene expression profilingTreatmentExpression profilingDiverse spectrumPrognosis
2011
The important role of radiation therapy in early-stage diffuse large B-cell lymphoma: time to review the evidence once again
Bindra RS, Yahalom J. The important role of radiation therapy in early-stage diffuse large B-cell lymphoma: time to review the evidence once again. Expert Review Of Anticancer Therapy 2011, 11: 1367-1378. PMID: 21929311, DOI: 10.1586/era.11.88.Peer-Reviewed Original ResearchConceptsEarly-stage diffuse large B-cell lymphomaDiffuse large B-cell lymphomaLarge B-cell lymphomaB-cell lymphomaLocalized diseaseClinical trialsRadiation therapyAlternative treatment regimenSignificant survival benefitCombined-modality therapyRecent clinical trialsRandomized clinical trialsCombination of chemotherapyIntensive immunochemotherapyConsolidation radiotherapySurvival benefitTreatment regimenRetrospective studyHodgkin's lymphomaMultimodality approachCommon subtypeSuperior efficacyLocal controlAppropriate managementLymphoma
2010
Overview of the Lymphoid Neoplasms
Podoltsev N, Lacy J, Vose J. Overview of the Lymphoid Neoplasms. 2010, 3-39. DOI: 10.1007/978-1-4419-7668-0_1.Peer-Reviewed Original ResearchNon-Hodgkin lymphomaHodgkin's lymphomaPathogenesis of lymphomaHistologic featuresEtiologic factorsCommon subtypeWHO classificationTreatment outcomesCell neoplasmsClinical aspectsClinical groupingLymphoid malignanciesLymphoma pathogenesisLymphoid cellsLymphoid neoplasmsNormal lymphocytesLymphomaImmune systemDistinct subtypesNeoplasmsLymphocyte developmentSecond portionPathogenesisSubtypesGenetic events
2005
Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging.
Cha S, Tihan T, Crawford F, Fischbein NJ, Chang S, Bollen A, Nelson SJ, Prados M, Berger MS, Dillon WP. Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging. American Journal Of Neuroradiology 2005, 26: 266-73. PMID: 15709123, PMCID: PMC7974081.Peer-Reviewed Original ResearchConceptsBlood volume measurementsDSC-MR imagingLow-grade oligodendrogliomasMR imagingWorld Health Organization grade II astrocytomaGrade II astrocytomasContrast-enhanced MR imagingCerebral blood volume measurementsLow-grade astrocytomasContrast-enhanced MRLow-grade gliomasSpecific tumor markersDynamic susceptibility contrast-enhanced MR imagingMaximum relative CBVDiagnosis of gliomaSurgical resectionConsecutive patientsHistologic confirmationHistologic subtypeCommon subtypeHistopathologic evaluationMorphologic aberrationsTumor vascularityTumor markersAnatomic imaging
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply